Anti-Nicotine [NIC9D9]

Absolute Antibody

Anti-Nicotine [NIC9D9]

7

The binding characterization of this antibody to nicotine-BSA hapten was done using ELISA (PMID: 11397142). A study to determine the effect of vaccination with this antibody towards a series of nicotine challenges and testing sessions was conducted. Passive immunization with NIC9D9 resulted in a 66.9% decrease in locomotor activity versus a 3.4% decrease in controls (PMID: 14738965). This antibody was also used in the generation of an adeno-associated virus (AAV) gene transfer vector which persistently expresses this antibody in vivo and prevents nicotine from reaching its receptors in the brain. This vector is called AAVantiNic and it generates an antibody similar to Nic9D9 that binds nicotine with an affinity of Kd= 43 nM. The mice treated with this vector showed 7 times greater amounts of nicotine in the serum of which 83% was bound to IgG. The vector blocked nicotine-mediated alterations in arterial blood pressure, heart rate and locomotor activity (PMID: 22745437).

ELISA

ELISA; immunotherapy

Research Use Only

Monoclonal

NIC9D9

Mouse

IgG1

Other Species

Species independent

The original antibody was generated by immunizing mice with keyhole limpet hemocyanin (KLH) conjugated nicotine hapten.

-20°C,2°C to 8°C

41116161